Tuesday, October 21, 2014

In conversation with Tony Pullen

In conversation with Tony Pullen

April 1, 2014 by · Leave a Comment 

Tweet Tony Pullen is one of the deans of Canadian capital markets. His career in biotech traces its roots to 1985 as an advisor to Cangene, which merged with Emergent BioSolutions (NYSE:EBS) in February. He also was instrumental in raising the initial capital for MDS Health Ventures, which went on to become MDS Capital Corp., […]

Trimel in pre-NDA meeting with FDA next month

Trimel in pre-NDA meeting with FDA next month

January 15, 2013 by · 1 Comment 

Tweet Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug application at the end of March. “The pivotal results corroborated what we had anticipated in our statistical modeling and […]

Roth starts Trimel at buy

Roth starts Trimel at buy

October 16, 2012 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Trimel Pharmaceuticals (TSX:TRL) with a “buy” rating and 12-month price target of $3, citing expectations for positive CompleoTRT data and a potential marketing partnership. The stock closed at $1.59 on Monday. CompleoTRT is a testosterone replacement for men. The testosterone market is already a $2-billion market, and […]

Trimel hosts Tefina investigator meeting

Trimel hosts Tefina investigator meeting

June 19, 2012 by · Leave a Comment 

Tweet Trimel Pharmaceuticals (TSX:TRL) recently hosted a two-day meeting in Chicago with leading investigators in the study of new treatments for female sexual dysfunction. The purpose of the meeting was to allow the company to review the trial protocol for its ambulatory Phase 2 clinical study investigating the use of Tefina for the treatment of […]

Trimel cleared for Tefina study in Canada

Trimel cleared for Tefina study in Canada

June 15, 2012 by · Leave a Comment 

Tweet Health Canada has provided Trimel Pharmaceuticals (TSX:TRL) with a no objection letter, permitting patient enrolment in Canada for the Tefina Phase 2 ambulatory study exploring a use-as-required treatment for women experiencing female orgasmic disorder (FOD), or more commonly referred to as anorgasmia. FOD affects one-in-five women worldwide. Currently, there are no approved FOD treatments, […]

Trimel has positive early data from CompleoTRT trial

Trimel has positive early data from CompleoTRT trial

May 29, 2012 by · Leave a Comment 

Tweet Trimel Pharmaceuticals (TSX:TRL) has completed a preliminary review of early data from a Phase 3 clinical trial, indicating that 79.9% of patients treated with CompleoTRT achieved an average serum testosterone (AST) level within the normal range. The company said the results exceed the threshold required by the FDA to confirm the efficacy of a […]

Trimel nears full enrolment for CompleoTRT trial

Trimel nears full enrolment for CompleoTRT trial

May 23, 2012 by · Leave a Comment 

Tweet Trimel Pharmaceuticals (TSX:TRL) has informed individual investigator clinical trial sites that the entire study is approaching full enrolment. Sites have been put on alert to closely monitor and report ongoing recruitment results in order to avoid added costs associated with over-enrolment. CompleoTRT or low testosterone is in development for the treatment of male hypogonadism, […]

Trimel begins Phase 2 trial for Tefina

Trimel begins Phase 2 trial for Tefina

May 17, 2012 by · Leave a Comment 

Tweet Trimel Pharmaceuticals (TSX:TRL) has initiated patient enrollment into one of the largest clinical studies to ever explore a “use-as-required” treatment for women experiencing anorgasmia, which is a persistent or recurrent delay in, or absence of, orgasm following a normal sexual excitement phase that can result in marked personal distress or interpersonal difficulties. The Company […]

Email Newsletters with Constant Contact
Google+